Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Saved in:
| Title: | Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. |
|---|---|
| Authors: | Harbeck, N.1 (AUTHOR) nadia.harbeck@med.uni-muenchen.de, Modi, S.2 (AUTHOR), Pusztai, L.3 (AUTHOR), Ohno, S.4 (AUTHOR), Wu, J.5 (AUTHOR), Kim, S.-B.6 (AUTHOR), Yoshida, A.7 (AUTHOR), Fabi, A.8 (AUTHOR), Cao, X.9,10 (AUTHOR), Joseph, R.11 (AUTHOR), Li, R.12 (AUTHOR), Żurawski, B.13 (AUTHOR), Escrivá-de-Romaní, S.14,15 (AUTHOR), Meneguetti, R.16 (AUTHOR), Supavavej, A.17 (AUTHOR), Chen, S.-C.18 (AUTHOR), Liu, Z.19 (AUTHOR), Kelly, C.20,21 (AUTHOR), Curigliano, G.22,23 (AUTHOR), Symmans, W.F.24 (AUTHOR) |
| Source: | Annals of Oncology. Feb2026, Vol. 37 Issue 2, p166-179. 14p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 190962234 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Harbeck%2C+N%2E%22">Harbeck, N.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> nadia.harbeck@med.uni-muenchen.de</i><br /><searchLink fieldCode="AR" term="%22Modi%2C+S%2E%22">Modi, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pusztai%2C+L%2E%22">Pusztai, L.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohno%2C+S%2E%22">Ohno, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+J%2E%22">Wu, J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+S%2E-B%2E%22">Kim, S.-B.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yoshida%2C+A%2E%22">Yoshida, A.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fabi%2C+A%2E%22">Fabi, A.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+X%2E%22">Cao, X.</searchLink><relatesTo>9,10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Joseph%2C+R%2E%22">Joseph, R.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+R%2E%22">Li, R.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Żurawski%2C+B%2E%22">Żurawski, B.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Escrivá-de-Romaní%2C+S%2E%22">Escrivá-de-Romaní, S.</searchLink><relatesTo>14,15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meneguetti%2C+R%2E%22">Meneguetti, R.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Supavavej%2C+A%2E%22">Supavavej, A.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+S%2E-C%2E%22">Chen, S.-C.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Z%2E%22">Liu, Z.</searchLink><relatesTo>19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kelly%2C+C%2E%22">Kelly, C.</searchLink><relatesTo>20,21</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curigliano%2C+G%2E%22">Curigliano, G.</searchLink><relatesTo>22,23</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Symmans%2C+W%2EF%2E%22">Symmans, W.F.</searchLink><relatesTo>24</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Feb2026, Vol. 37 Issue 2, p166-179. 14p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=190962234 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.10.019 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 14 StartPage: 166 Titles: – TitleFull: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Harbeck, N. – PersonEntity: Name: NameFull: Modi, S. – PersonEntity: Name: NameFull: Pusztai, L. – PersonEntity: Name: NameFull: Ohno, S. – PersonEntity: Name: NameFull: Wu, J. – PersonEntity: Name: NameFull: Kim, S.-B. – PersonEntity: Name: NameFull: Yoshida, A. – PersonEntity: Name: NameFull: Fabi, A. – PersonEntity: Name: NameFull: Cao, X. – PersonEntity: Name: NameFull: Joseph, R. – PersonEntity: Name: NameFull: Li, R. – PersonEntity: Name: NameFull: Żurawski, B. – PersonEntity: Name: NameFull: Escrivá-de-Romaní, S. – PersonEntity: Name: NameFull: Meneguetti, R. – PersonEntity: Name: NameFull: Supavavej, A. – PersonEntity: Name: NameFull: Chen, S.-C. – PersonEntity: Name: NameFull: Liu, Z. – PersonEntity: Name: NameFull: Kelly, C. – PersonEntity: Name: NameFull: Curigliano, G. – PersonEntity: Name: NameFull: Symmans, W.F. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: Feb2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 37 – Type: issue Value: 2 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
